SCIENTIFIC REPORTS

OPEN

A *de novo* deletion mutation in *SOX10* in a Chinese family with Waardenburg syndrome type 4

Xiong Wang^{1,*}, Yaowu Zhu^{1,*}, Na Shen¹, Jing Peng¹, Chunyu Wang¹, Haiyi Liu² & Yanjun Lu¹

Received: 06 October 2016

Accepted: 21 December 2016

Published: 27 January 2017

Waardenburg syndrome type 4 (WS4) or Waardenburg-Shah syndrome is a rare genetic disorder with a prevalence of $<1/1,000,000$ and characterized by the association of congenital sensorineural hearing loss, pigmentary abnormalities, and intestinal aganglionosis. There are three types of WS4 (WS4A–C) caused by mutations in endothelin receptor type B, endothelin 3, and SRY-box 10 (*SOX10*), respectively. This study investigated a genetic mutation in a Chinese family with one WS4 patient in order to improve genetic counselling. Genomic DNA was extracted, and mutation analysis of the three WS4 related genes was performed using Sanger sequencing. We detected a *de novo* heterozygous deletion mutation [c.1333delT (p.Ser445Glnfs*57)] in *SOX10* in the patient; however, this mutation was absent in the unaffected parents and 40 ethnicity matched healthy controls. Subsequent phylogenetic analysis and three-dimensional modelling of the *SOX10* protein confirmed that the c.1333delT heterozygous mutation was pathogenic, indicating that this mutation might constitute a candidate disease-causing mutation.

Waardenburg syndrome (WS), also known as auditory pigmentary syndrome, is characterized by congenital sensorineural deafness, dystopia canthorum, and pigmentary abnormalities affecting the hair, skin, and eyes and occurring with a frequency of $1/40,000^{1,2}$. WS is clinically and genetically heterogeneous and is classified into four types (WS1–4) caused by mutations of paired box 3 (*PAX3*), melanogenesis-associated transcription factor (*MITF*), endothelin 3 (*EDN3*), endothelin receptor type B (*EDNRB*), snail-family transcriptional repressor 2 (*SNAIL2*), and SRY-box 10 (*SOX10*)^{3,4}. WS1 and WS2 are the most frequent types, whereas WS4 constitutes a rare disorder^{5,6}.

WS4 is also known as Waardenburg-Shah syndrome (OMIM 277580) and is characterized by hearing loss, depigmentation, and aganglionic megacolon (Hirschsprung disease). WS4 includes three subtypes [WS4A–C (OMIM 277580, 613265, and 613266)] caused by mutations in *EDNRB*, *EDN3*, and *SOX10*, respectively^{7–9}. Mutations in *EDNRB* and *EDN3* are inherited in the autosomal recessive (AR) or autosomal dominant (AD) form, whereas the *SOX10* mutation is inherited as AD^{10–13} and found in ~50% of WS4 patients^{1,6}, with >30 WS4-related mutations reported in the Human Gene Mutation Database. *SOX10* is a critical transcription factor, targeting *MITF*, tyrosinase, myelin protein zero, gap junction protein beta 1, ret proto-oncogene, and *EDNRB* during neural-crest-derived cell migration and differentiation. Additionally, *SOX10* modulates the expression of its target genes and the migration of pluripotent neural crest cells from the neural tube during embryogenesis^{14,15}.

In this study, we conducted detailed clinical and genetic analysis of a Chinese family with a WS4-afflicted child. A *de novo* heterozygous deletion mutation [c.1333delT (p.Ser445Glnfs*57)] in *SOX10* was detected in the patient, although this mutation was absent in the unaffected parents and 40 ethnicity matched healthy controls. Our findings indicated that this mutation might be a candidate disease-causing mutation.

Methods

Subjects and clinical evaluation. The patient, his unaffected parents, and 40 unrelated healthy controls were included in this study, and ophthalmic and audiological examinations were performed. Written informed consent was obtained from all participants, and this study was formally approved by the Ethics Committee of

¹Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. ²Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to H.L. (email: liu_haiyi@163.com) or Y.L. (email: junyanlu_2000@163.com)

Figure 1. Clinical features of the patient. (a) Photograph of the patient presented with blue iride of the right eye and two different colours of the left eye. (b) The barium enema examination of the colon of the patient showed megacolon congenitum.

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. All procedures were performed in accordance with the approved guidelines.

Mutation screening. Peripheral blood was collected, and genomic DNA was extracted using a DNeasy blood and tissue kit from Qiagen (Hilden, Germany). Polymerase chain reaction (PCR) was performed to amplify all coding exons and intron/exon boundaries of the *EDNRB*, *EDN3*, *SOX10*, *PAX3*, *MITF*, and *SNAIL2* genes. Some of the primers used in the study were referenced from a master's thesis (title here, Dong Siqi; Chinese PLA General Hospital, Beijing, China), and other primers were designed using Primer 5. Primers are shown in Table 1. PCR of the *SOX10* exons was performed in a total volume of 50 μ L containing 60 ng of genomic DNA, 400 nM each of the forward and reverse primers, 40 mM dNTPs, and 2.5 U LA Taq DNA polymerase with GC buffer I from TAKARA (Tokyo, Japan). The amplification consisted of an initial denaturation stage at 94 °C for 3 min, followed by 35 cycles consisting of denaturation at 94 °C for 30 s, annealing for 30 s at 60 °C, and extension at 72 °C for 50 s, with an extension step performed at 72 °C for 3 min. Amplification of exons for the remaining genes was performed using 2 $\times$ PCR master mix under similar conditions, except for annealing at 57 °C. PCR products were purified and sequenced using an ABI 3500 Dx genetic analyser with a BigDye terminator cycle sequencing ready reaction kit (Applied Biosystems, Foster City, CA, USA), and the sequences were analysed using NCBI BLAST (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>).

Paternity testing and haplotype analysis. Five short tandem-repeat markers (STRs; D22S283, D22S1177, D22S1045, D22S272, and D22S423) ranging from chr22:36750705 to chr22:40382524 and five single nucleotide polymorphisms (SNPs; rs139873, rs139885, rs4821733, rs3952, and rs5756908) were selected from the UCSC Genome Browser (<http://genome.ucsc.edu/>), and linkage-disequilibrium analysis was performed based on LD TAG SNP selection (TagSNP; <http://snpinfo.niehs.nih.gov/snpinfo/snpntag.php>). STR and SNP primers are shown in Table 1.

Protein structure prediction. Both the wild-type and mutated *SOX10* protein sequences were used to perform protein structure prediction using I-TASSER (<http://zhanglab.ccmb.med.umich.edu/I-TASSER/>) as previously reported^{16–19}. In I-TASSER, the B-factor, which indicates the extent of the inherent thermal mobility of residues/atoms in proteins, is calculated from threading template proteins from the Protein Data Bank along with sequence profiles derived from sequence databases. The normalized B-factor of the target protein was defined by $B = (B' - u)/s$, where B' represents the raw B-factor value, and u and s represent the mean and standard deviation of the raw B-factors along the sequence, respectively.

Primer name	Sequence
SOX10 E1F (765 bp)	AGATGGGTTTAGCTGGAGCA
SOX10 E1R (765 bp)	ACCTGGTCTTCCAGCCCTAT
SOX10 E2F (686 bp)	GTTATTCTTGGGCCTCACA
SOX10 E2R (686 bp)	CTTGTCCAGTAGGATCAGC
SOX10 E3A F (686 bp)	GCTGCCAAAATGTGAAACTTA
SOX10 E3A R (686 bp)	GAGTGGCCATAATAGGGTCC
SOX10 E3BF (561 bp)	AGCCAGGTGAAGACAGAGA
SOX10 E3BR (561 bp)	TCTGTCCAGCCTGTTCTCCT
EDN3 E1 F (407 bp)	CAGAAGCCAGAAAAGCCCGA
EDN3 E1 R (407 bp)	CCAGGCAAGAGTTTGCTCCC
EDN3 E2 F (597 bp)	TTTGCAGACATTTGCTTGC
EDN3 E2 R (597 bp)	CCTGACCTGCAGAAGAGACC
EDN3 E3 F (480 bp)	GGTGACAGTTCCTCCAGA
EDN3 E3 R (480 bp)	CCCACAGGACGACAGTAGGT
EDN3 E4 F (607 bp)	CGTCTGTGAAACCCAGTGTG
EDN3 E4 R (607 bp)	CATCACTGCCCAGAGCTACA
EDN3 E5 F (424 bp)	GGCTCGGAAATTGCTGAGAAG
EDN3 E5 R (424 bp)	TCTTTGGGTGGGTGTTCTGC
EDNRB E1 F(748 bp)	CTTTTGAGCGTGGATACTGG
EDNRB E1 R(748 bp)	AGGGAGCTAAAGGGAAGCTC
EDNRB E2 F (498 bp)	AACACACTTCTGTCCCATAC
EDNRB E2 R (498 bp)	TTCTACTGCTGTCCATTTGG
EDNRB E3 F (555 bp)	CTGTGGGAATCACTGTGCTG
EDNRB E3 R (555 bp)	AGCTTGAGTCATTGATCACCA
EDNRB E4 F (432 bp)	TGTTTCAGTAAGTGTGGCCTGA
EDNRB E4 R (432 bp)	CAAGAAAAAGGAAATATGCTCTGG
EDNRB E5 F (466 bp)	CACTTCGGTTCCTTCACA
EDNRB E5 R (466 bp)	CTTCCCTGTCCCTCTCAACA
EDNRB E6 F (493 bp)	GAGGGGACACAGACAGAGA
EDNRB E6 R (493 bp)	GCAGTAGGGAGTGGCTGACT
EDNRB E7 F (466 bp)	AAGAGGGAAAATAAAGAGCACTG
EDNRB E7 R (466 bp)	TTCTTTCCATGCCGTAACA
PAX3 E1F (620 bp)	GAACATTTGCCAGACTCGT
PAX3 E1R (620 bp)	TCCAAAACAACAGGGACAAGT
PAX3-2F (503 bp)	CCGATGTCGAGCAGTTTCAG
PAX3-2R (503 bp)	CGCACCTTCACAAACCTCAG
PAX3-3F (420 bp)	TGGGATGTGTTCTGGTCTG
PAX3-3R (420 bp)	TCCAATAGCTGAGATCGA
PAX3-4F (383 bp)	CTGGAGAAGGATGAGGATGT
PAX3-4R (383 bp)	CGTCAGATCACCAATGTCAG
PAX3-5F (508 bp)	TACGGATTGGTTAGACTTGT
PAX3-5R (508 bp)	AACAATATGCATCCCTAGTAA
PAX3-6F (445 bp)	CAACACAGAAGGCAGAGA
PAX3-6R (445 bp)	ATAGGTACGTTTCAGGACAA
PAX3-7F (586 bp)	TGTGCAGAGATAGGTGTGAC
PAX3-7R (586 bp)	TTTGATGAAGCCAGTAGGA
PAX3 E8F (543 bp)	GTTATTCTTTCAGCTGTAGGC
PAX3 E8R (543 bp)	GTCTCAACAATTAATAACCGC
MITF E1F (630 bp)	GGAGTTGCACTAGCGGTGTC
MITF E1R (630 bp)	GCTCCATCCGAGCTTCCTA
MITF E2F (628 bp)	GCCTGATAAAAATGCCTTGA
MITF E2R (628 bp)	AGCCACGTAAGAATTAAGGGA
MITF E3F (564 bp)	GCACAGTGCCTGGTACATAAC
MITF E3R (564 bp)	TGCTCTACCCCAATAACCC
MITF E4 F (310 bp)	TCATCTTTGGTCAGATTCCAC
Continued	

Primer name	Sequence
MITF E4 R (310 bp)	TGCTTAAGTTTTCAGGAAGGTG
MITF-5F (343 bp)	GACCATTATTGCTTTGGGTAAAA
MITF-5R (343 bp)	TGTGATCCTGAGATAATTCTCCATT
MITF-6F (425 bp)	TGAGGAGATCCTGTACCTCTCTT
MITF-6R (425 bp)	AAAAGTTACGTCCATGAGTTGG
MITF-7F (350 bp)	GCTTTTGAAAACATGCAAGC
MITF-7R (350 bp)	GCTGTAGGAATCAACTCTCCTCT
MITF E8 F (527 bp)	AAGGGCTTTGGAAATGGTAA
MITF E8 R (527 bp)	AGAAAGCCACCTCCTCACAA
MITF-9F (425 bp)	CTTATCCATGTAACCAAGCA
MITF-9R (425 bp)	CACACACACAGAATCCACAAA
MITF-10F (646 bp)	CTAATGACGCGCATCTACCA
MITF-10R (646 bp)	TCCTGGGCTATTGATAAAGCA
SNAI2 E1 F (388 bp)	CGGGCTCAGTTCGTAAAGGA
SNAI2 E1 R (388 bp)	GCTCCCTTTCAGGACACTGTTA
SNAI2 E2 AF (534 bp)	GCCCTCCTAAATGGGTCTATC
SNAI2 E2 AR (534 bp)	TTTCTAGACTGGGCATCGC
SNAI2 E2 BF (565 bp)	GCCCCATTAGTGATGAAGAG
SNAI2 E2 BR (565 bp)	GATCTTTGAGACCAACCTTC
SNAI2 E3 F (556 bp)	GGTTTGTCTGCTTCTCATTAT
SNAI2 E3 R (556 bp)	TCTCTCAATCTAGCCATCAGC
D22S283 F (217 bp)	FAM-ACAAACACTTCTACAGTCTGG
D22S283 R (217 bp)	TGAGCCACGGAGATCTTTC
D22S1177 F (186 bp)	FAM-GCCACTCTGGCACCAT
D22S1177 R (186 bp)	AGCTGTNAGCAAGCAGG
D22S1045 F (153 bp)	FAM-GCTAGATTTCCCGATGAT
D22S1045 R (153 bp)	ATGTAAAGTGCTCTCAAGAGTGC
D22S272 F (132 bp)	FAM-GAGTTTGTGCTTGCCTGGCAC
D22S272 R (132 bp)	AATGCACGACCCACCTAAAG
D22S423 F (123 bp)	FAM-CACACTGGTACACACATACACA
D22S423 R (123 bp)	AAACCAACTGACTCGTTTAGG
rs139885 F (625 bp)	CACCCATGCCTACTGTCTTC
rs139885 R (625 bp)	GAGACCCTGGACCACATACA
rs3952 F (263 bp)	CTTGCTGTAGCCTTGGGAATA
rs3952 R (263 bp)	GTAGAGGGAGGTGGCGAGA
rs5756908 F (306 bp)	AGTTTCCCAAAGATACTGTCCC
rs5756908 R (306 bp)	CCAGTTAGTCCCTCCTCCAA
rs4821733 F (434 bp)	GCAGGCATTGGCATCACC
rs4821733 R (434 bp)	AAATTGCTTGAATGCGGGAG
rs139873 F (374 bp)	AAAAAGACTCCTGGCTTCCA
rs139873 R (374 bp)	CCCACAGTGCTCGGATTC

Table 1. Primers used in this study.

Results

Clinical findings. A 1-year-old male patient was referred to our hospital with the chief complaint of Hirschsprung disease accompanied by heterochromia iridis and congenital hearing loss. Based on these clinical features, he was first suspected to be a WS4 patient. Neither parent of the patient exhibited similar symptoms (Fig. 1).

Identification of a novel *SOX10* heterozygous deletion mutation. A heterozygous deletion mutation (c.1333delT) in *SOX10* was identified in the patient, resulting in replacement of the 445th Ser with Gln and a shift in the reading frame to produce a longer protein consisting of 501 amino acids (p.Ser445Glnfs*57) as compared with the wild-type *SOX10* protein (467 amino acids; Fig. 2, Table 2). We subsequently verified that this mutation did not exist in any of the widely used genomic databases, confirming that c.1333delT constitutes a novel deletion mutation. Moreover, this mutation was not found in the unaffected parents or in 40 unrelated healthy control subjects. However, a heterozygous missense mutation (c.1363C > A) in *MITF* was found in both the patient and his father, but not in his mother (Fig. 2). This mutation was found in the dbSNP (<https://www.ncbi.nlm.nih.gov/projects/SNP/>) and ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) databases (rs78962087) and is reportedly benign. Furthermore, no mutation was found in the *EDN3*, *EDNRB*, *PAX3*, or *SNAI2* genes.

Figure 2. Identification of a novel *SOX10* heterozygous deletion mutation. Sequence chromatographs of the *SOX10* and *MITF* genes of the Chinese family. (a) The heterozygous mutation in *SOX10* [c.1333delT (p.Ser445Glnfs*57)] was only found in the patient, but not his father or mother. (b) The heterozygosity mutation in *MITF* [c.1363C > A (p.Leu455Ile)] found in the patient and his father, but not his mother.

These results suggested that the heterozygous deletion mutation (c.1333delT) in *SOX10* might be associated with the WS4 phenotype of the patient.

Paternity testing and haplotype analysis. *SOX10*c.1333delT is located in chr22:38369570. To confirm the paternity of the father, five STRs (D22S283, D22S1177, D22S1045, D22S272, and D22S423) ranging from chr22:36750705 to chr:40382524 and five SNPs (rs139873, rs139885, rs4821733, rs3952, and rs5756908) ranging from chr22:38359666 to chr:38476579 were selected from the UCSC Genome Browser (<http://genome.ucsc.edu/>) based on their proximity to the mutation site. Paternity testing by haplotype analysis confirmed that these were the biological parents of the patient with WS4 (Figs 3 and 4).

Protein structure prediction. The wild-type *SOX10* protein consists of 467 amino acids and contains three helices, whereas the *SOX10* deletion mutation (c.1333delT) results in a protein consisting of 501 amino acids with four helices (Fig. 5). The wild-type and mutant variants shared identical sequences in the first 444 amino acids, with differences occurring after this point.

Discussion

WS is classified into four primary phenotypes. WS1 is caused by mutations in *PAX3* and distinguished by the presence of dystopia canthorum (lateral displacement of the inner canthi). WS2 is caused by mutations in *MITF*, *SOX10*, or *SNAI2* and distinguished from type 1 by the absence of dystopia canthorum. WS3 is caused by mutations in *PAX3*, with patients presenting both dystopia canthorum and upper limb abnormalities. WS4 is caused by mutations in *EDNRB*, *EDN3*, or *SOX10*, with patients presenting with phenotypes associated with Hirschsprung disease^{1,20–23}. Here, we described a Chinese patient with clinical features of WS4 and identified a novel heterozygous deletion mutation [c.1333delT (p.Ser445Glnfs*57)] in *SOX10* that was absent in his unaffected parents and 40 ethnicity matched healthy controls. To the best of our knowledge, this constitutes the first report of this mutation, suggesting it as a candidate disease-causing mutation.

Figure 3. Paternity testing and haplotype analysis. 601, patient; 602, father; 603, mother.

Gene	Variant	Protein level	Type	Father	Mother	Report
Sox10	c.1333delT	p.Ser445Glnfs*57	heterozygous	Normal	Normal	No
MITF	c.1363C>A	p.Leu455Ile	heterozygous	heterozygous	Normal	Yes

Table 2. Genetic variants found in this family with WS4.

SOX10 is located on chromosome 22 and encodes an essential DNA-binding nuclear transcription factor consisting of 467 amino acids and belonging to the SOX family involved in modulating embryonic development and determining cell fate. *SOX10* may act as a transcriptional activator upon forming a complex with other proteins and/or as a nucleocytoplasmic shuttle protein critical for neural crest and peripheral nervous system development^{24–27}. Mutations in this gene are associated with WS4 and are present in ~50% of WS4 patients^{6,28}.

SOX10 contains a highly conserved high mobility group (HMG) DNA-binding domain and a C-terminal transactivation (TA) domain that is enriched in serine, proline, and acidic residues^{29,30}. Additionally, *SOX10* contains two separate TA domains, with one localized in the C-terminal region and the other in the central region of the structure. The C-terminal TA domain is frequently involved in various interactions, whereas the TA domain located in the centre of the structure is only involved in TA-related activity in certain cell types and under certain developmental conditions³¹. *SOX10* binds to the promoters of its target genes via the HMG domain, with several studies reporting the importance of the TA domain for inducing transcriptional activation of its target genes³². Wang *et al.*³² identified a c.1063C > T (p.Q355*) mutation in *SOX10* in a family with WS4 and reported that the mutated *SOX10* variant retained nuclear localization and DNA-binding capabilities comparable to those observed in wild-type *SOX10*; however, the mutated *SOX10* variant was unable to activate transcription of *MITF* via its promoter and acted as a dominant-negative repressor as compared with activity associated with wild-type *SOX10*^{7,33}. In this study, we detected a c.1333delT (p.Ser445Glnfs*57) mutation in *SOX10* in a family with WS4, with the mutated *SOX10* variant sharing sequence homology with only the N-terminal 444 amino acids of the wild-type protein. Furthermore, we identified an additional helix in the C-terminal region of the mutated *SOX10* variant (Fig. 4), which may affect its normal biological function.

Figure 4. SNP analysis of the Chinese family with WS4. Five SNPs (rs139873, rs139885, rs4821733, rs3952, and rs5756908) were selected.

Figure 5. Protein structure prediction. (a) Wild-type SOX10 protein structure. (b) The mutated SOX10 protein structure.

In conclusion, here, we described a *de novo* heterozygous deletion mutation [c.1333delT (p.Ser445Glnfs*57)] in SOX10 identified in a Chinese family with WS4. Our analyses indicated that this mutation might constitute a candidate disease-causing mutation associated with WS4.

References

1. Pingault, V. *et al.* Review and update of mutations causing Waardenburg syndrome. *Hum Mutat* **31**, 391–406, doi: 10.1002/humu.21211 (2010).
2. Zaman, A., Capper, R. & Baddoo, W. Waardenburg syndrome: more common than you think! *Clin Otolaryngol* **40**, 44–48, doi: 10.1111/coa.12312 (2015).
3. Song, J. *et al.* Hearing loss in Waardenburg syndrome: a systematic review. *Clin Genet*, doi: 10.1111/cge.12631 (2015).
4. Toriello, H. V. Pigmentary anomalies and hearing loss. *Adv Otorhinolaryngol* **70**, 50–55, doi: 10.1159/000322471 (2011).
5. Doubaj, Y. *et al.* A novel mutation in the endothelin B receptor gene in a moroccan family with shah-waardenburg syndrome. *Mol Syndromol* **6**, 44–49, doi: 10.1159/000371590 (2015).
6. Fernandez, R. M. *et al.* Waardenburg syndrome type 4: report of two new cases caused by SOX10 mutations in Spain. *Am J Med Genet A* **164A**, 542–547, doi: 10.1002/ajmg.a.36302 (2014).
7. Wang, H. H. *et al.* Identification and functional analysis of a novel mutation in the SOX10 gene associated with Waardenburg syndrome type IV. *Gene* **538**, 36–41, doi: 10.1016/j.gene.2014.01.026 (2014).
8. Mahmoudi, A. *et al.* Shah-Waardenburg syndrome. *Pan Afr Med J* **14**, 60, doi: 10.11604/pamj.2013.14.60.1543 (2013).
9. Parthey, K. *et al.* SOX10 mutation with peripheral amyelination and developmental disturbance of axons. *Muscle Nerve* **45**, 284–290, doi: 10.1002/mus.22262 (2012).
10. Puffenberger, E. G. *et al.* A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease. *Cell* **79**, 1257–1266 (1994).
11. Baynash, A. G. *et al.* Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons. *Cell* **79**, 1277–1285 (1994).
12. Pingault, V. *et al.* SOX10 mutations in patients with Waardenburg-Hirschsprung disease. *Nat Genet* **18**, 171–173, doi: 10.1038/ng0298-171 (1998).
13. Syrris, P., Carter, N. D. & Patton, M. A. Novel nonsense mutation of the endothelin-B receptor gene in a family with Waardenburg-Hirschsprung disease. *Am J Med Genet* **87**, 69–71 (1999).
14. Bondurand, N. & Sham, M. H. The role of SOX10 during enteric nervous system development. *Dev Biol* **382**, 330–343, doi: 10.1016/j.ydbio.2013.04.024 (2013).
15. Wegner, M. From head to toes: the multiple facets of Sox proteins. *Nucleic Acids Res* **27**, 1409–1420 (1999).
16. Yang, J. *et al.* The I-TASSER Suite: protein structure and function prediction. *Nat Methods* **12**, 7–8, doi: 10.1038/nmeth.3213 (2015).
17. Yang, J. & Zhang, Y. I-TASSER server: new development for protein structure and function predictions. *Nucleic Acids Res* **43**, W174–181, doi: 10.1093/nar/gkv342 (2015).
18. Roy, A., Kucukural, A. & Zhang, Y. I-TASSER: a unified platform for automated protein structure and function prediction. *Nat Protoc* **5**, 725–738, doi: 10.1038/nprot.2010.5 (2010).
19. Zhang, Y. I-TASSER server for protein 3D structure prediction. *BMC Bioinformatics* **9**, 40, doi: 10.1186/1471-2105-9-40 (2008).
20. Milunsky, J. M. In *GeneReviews (R)* (eds Pagon, R. A. *et al.*) (1993).
21. Nayak, C. S. & Isaacson, G. Worldwide distribution of Waardenburg syndrome. *Ann Otol Rhinol Laryngol* **112**, 817–820 (2003).
22. Newton, V. E. Clinical features of the Waardenburg syndromes. *Adv Otorhinolaryngol* **61**, 201–208 (2002).
23. Dourmishev, A. L., Dourmishev, L. A., Schwartz, R. A. & Janniger, C. K. Waardenburg syndrome. *Int J Dermatol* **38**, 656–663 (1999).
24. Lecerf, L. *et al.* An impairment of long distance SOX10 regulatory elements underlies isolated Hirschsprung disease. *Hum Mutat* **35**, 303–307, doi: 10.1002/humu.22499 (2014).
25. Chen, K. *et al.* De novo dominant mutation of SOX10 gene in a Chinese family with Waardenburg syndrome type II. *Int J Pediatr Otorhinolaryngol* **78**, 926–929, doi: 10.1016/j.ijporl.2014.03.014 (2014).
26. Pingault, V. *et al.* SOX10 mutations mimic isolated hearing loss. *Clin Genet* **88**, 352–359, doi: 10.1111/cge.12506 (2015).
27. Chen, K. *et al.* Genetic counseling for a three-generation Chinese family with Waardenburg syndrome type II associated with a rare SOX10 mutation. *Int J Pediatr Otorhinolaryngol* **79**, 745–748, doi: 10.1016/j.ijporl.2015.03.006 (2015).
28. Amiel, J. *et al.* Hirschsprung disease, associated syndromes and genetics: a review. *J Med Genet* **45**, 1–14, doi: 10.1136/jmg.2007.053959 (2008).
29. Wegner, M. Secrets to a healthy Sox life: lessons for melanocytes. *Pigment Cell Res* **18**, 74–85, doi: 10.1111/j.1600-0749.2005.00218.x (2005).
30. Pusch, C. *et al.* The SOX10/Sox10 gene from human and mouse: sequence, expression, and transactivation by the encoded HMG domain transcription factor. *Hum Genet* **103**, 115–123 (1998).
31. Schreiner, S. *et al.* Hypomorphic Sox10 alleles reveal novel protein functions and unravel developmental differences in glial lineages. *Development* **134**, 3271–3281, doi: 10.1242/dev.003350 (2007).
32. Chaoui, A. *et al.* Identification and functional analysis of SOX10 missense mutations in different subtypes of Waardenburg syndrome. *Hum Mutat* **32**, 1436–1449, doi: 10.1002/humu.21583 (2011).
33. Bondurand, N. *et al.* Interaction among SOX10, PAX3 and MITF, three genes altered in Waardenburg syndrome. *Hum Mol Genet* **9**, 1907–1917 (2000).

Acknowledgements

This work was partially supported by the National Natural Science Foundation of China (No. 81500925).

Author Contributions

H.L. and Y.L. designed this work, X.W. and Y.Z. performed sequencing and analysis, N.S., C.W., and J.P. prepared figures, and X.W. wrote the manuscript.

Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Wang, X. *et al.* A de novo deletion mutation in SOX10 in a Chinese family with Waardenburg syndrome type 4. *Sci. Rep.* **7**, 41513; doi: 10.1038/srep41513 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>